How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|
| Pharma | 77.6 | 75.6 | 75.6 | 74.7 | -2.9 |
| Healthcare | 21.8 | 22.3 | 22.3 | 22.9 | +1.1 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 12.78% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| LUPIN | Pharma | 7.45% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| DRREDDY | Pharma | 6.68% | 7 | 2 | 5 | 1 | 7 | 0/2 | -0.3% |
| CIPLA | Pharma | 6.15% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| DIVISLAB | Pharma | 5.46% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| APOLLOHOSP | Healthcare | 5.27% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| MANKIND | Pharma | 4.03% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
| SAILIFE | Healthcare | 3.49% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| AJANTPHARM | Pharma | 3.46% | 8 | 10 | 1 | 4 | 3 | 0/2 | +14.6% |
| MAXHEALTH | Healthcare | 3.32% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| VIJAYA | Pharma | 2.80% | 8 | 10 | 4 | 2 | 1 | 0/2 | +37.0% |
| IPCALAB | Pharma | 2.57% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| GLAXO | Healthcare | 2.47% | 6 | 7 | 2 | 6 | 7 | 0/2 | +1.2% |
| GLAND | Pharma | 2.21% | 9 | 8 | 6 | 6 | 4 | 0/2 | +38.5% |
| ABBOTINDIA | Pharma | 2.09% | 4 | 9 | — | 8 | 7 | 0/2 | +0.6% |
| ALKEM | Pharma | 1.99% | 9 | 8 | 8 | 10 | 6 | 1/2 | +0.5% |
| LALPATHLAB | Healthcare | 1.85% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
| NH | Healthcare | 1.80% | 9 | 8 | 8 | 2 | 3 | 0/2 | +10.3% |
| AUROPHARMA | Pharma | 1.75% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| SYNGENE | Healthcare | 1.70% | 2 | 3 | 6 | 9 | 7 | 0/2 | -0.6% |
| PFIZER | Healthcare | 1.56% | 3 | 7 | 1 | 2 | 7 | 0/2 | -9.0% |
| EMCURE | Pharma | 1.52% | 8 | 10 | 5 | 5 | 3 | 0/2 | +9.8% |
| FORTIS | Healthcare | 1.42% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| PPLPHARMA | Pharma | 1.02% | 6 | 1 | 5 | 4 | 6 | 0/2 | +14.5% |
| ANTHEM | Pharma | 0.90% | 7 | 10 | 3 | 5 | 2 | 0/2 | -2.3% |
| BIOCON | Pharma | 0.68% | 6 | 1 | 10 | 5 | 3 | 0/2 | +12.5% |
| CONCORDBIO | Pharma | 0.16% | 5 | 4 | 2 | 1 | 4 | 0/2 | +19.8% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹182 (+82%), vs ₹169 for Nifty 500 (+69%) and ₹152 for Nifty 50 (+52%). Its relative-strength line ended at 120 vs Nifty 50 and 107 vs Nifty 500 — above 100, sustained outperformance.